한글목차

본 보고서는 주요 7개국(미국, EU 4개국(독일, 프랑스, 이탈리아, 스페인), 영국, 일본)의 수술 후 통증 치료제 SAF-312의 동향을 조사했으며, 치료제의 개요, 작용기전, 임상개발 데이터, 관련 법규, 시판 및 개발 중인 약품과의 경쟁 분석, 국가별 시장 개요, 시장 규모 추정 및 예측, SWOT 분석, 애널리스트의 견해 등을 정리하여 전해드립니다.

보고서 주요 내용:

• 수술 후 통증의 시장 시나리오는 광범위한 연구와 의료비 지출 증가로 인해 향후 몇 년 동안 변화할 것으로 예상됩니다.
• 각 회사는 질병을 치료 및 개선하고, 문제를 평가하고, SAF-312의 우위에 영향을 미칠 수 있는 기회를 얻기 위해 새로운 접근 방식에 초점을 맞춘 치료제를 개발하고 있습니다.
• 다른 신흥 수술 후 통증 치료제가 SAF-312와 치열한 시장 경쟁을 벌일 것으로 예상되며, 조만간 후발 신약이 출시되면 시장에 큰 영향을 미칠 것으로 보입니다.
• 법 규제 마일스톤과 개발 활동에 대한 자세한 설명을 통해 수술 후 통증에 대한 SAF-312의 현재 개발 시나리오를 제공합니다.
• 2027년부터 2032년까지 SAF-312의 예측 판매 데이터에 대한 상세한 분석을 통해 수술 후 통증에 대한 SAF-312의 전반적인 시나리오를 파악하여 치료제 포트폴리오에 대한 의사결정 과정에 도움을 줄 수 있습니다.

목차

제1장 보고서 소개

제2장 수술 후 통증의 SAF-312 개요

• 제품 상세
• 임상 개발
  • 임상 연구
  • 임상시험 정보
  • 안전성과 유효성
• 규제 마일스톤
• 기타 개발 활동
• 제품 프로파일

제3장 경쟁 구도(출시된 치료제)

제4장 경쟁 구도(후기 단계 신흥 치료제)

제5장 SAF-312 : 시장 평가

• 수술 후 통증에 대한 SAF-312 : 시장 전망
• 주요 7개국 분석
  • 수술 후 통증 치료제 SAF-312 시장 규모
• 국가별 시장 분석
  • 시장 규모 : 미국
  • 시장 규모 : 독일
  • 시장 규모 : 영국

제6장 SWOT 분석

제7장 애널리스트의 견해

제8장 부록

제9장 DelveInsight의 서비스 내용

제10장 면책사항

제11장 DelveInsight 소개

제12장 보고서 구입 옵션

영문목차

"SAF-312 Market Size, Forecast, and Emerging Insight - 2032" report provides comprehensive insights about SAF-312 for Postoperative pain in the seven major markets. A detailed picture of the SAF-312 for Postoperative pain in the 7MM, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan for the study period 2019 -2032 is provided in this report along with a detailed description of the SAF-312 for Postoperative pain. The report provides insights about mechanism of action, dosage and administration, as well as research and development including regulatory milestones, along with other developmental activities. Further, it also consists of future market assessments inclusive of the SAF-312 market forecast analysis for Postoperative pain in the 7MM, SWOT, analysts' views, comprehensive overview of market competitors, and brief about other emerging therapies in Postoperative pain.

Drug Summary:

Novartis Pharmaceuticals is developing an eyedrop named SAF312, a non-narcotic analgesic and TRPV cation channel antagonist, to treat postoperative ocular pain after PRK surgery and chronic ocular pain in subjects with undergone PRK or LASIK surgery.

The company has completed one Phase II trial for postoperative ocular pain after PRK surgery, and another study is undergoing to assess chronic ocular pain in subjects who have undergone PRK or LASIK surgery.

Scope of the Report:

The report provides insights into:

• A comprehensive product overview including the SAF-312 description, mechanism of action, dosage and administration, research and development activities in Postoperative pain.
• Elaborated details on SAF-312 regulatory milestones and other development activities have been provided in this report.
• The report also highlights the SAF-312 research and development activities in Postoperative pain across the United States, Europe, and Japan.
• The report also covers the patents information with expiry timeline around SAF-312.
• The report contains forecasted sales of SAF-312 for Postoperative pain till 2032.
• Comprehensive coverage of the late-stage emerging therapies for Postoperative pain.
• The report also features the SWOT analysis with analyst views for SAF-312 in Postoperative pain.

Methodology:

The report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight's team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

SAF-312 Analytical Perspective by DelveInsight

• In-depth SAF-312 Market Assessment

This report provides a detailed market assessment of SAF-312 for Postoperative pain in the seven major markets, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan. This segment of the report provides forecasted sales data from 2027 to 2032.

• SAF-312 Clinical Assessment

The report provides the clinical trials information of SAF-312 for Postoperative pain covering trial interventions, trial conditions, trial status, start and completion dates.

Report Highlights:

• In the coming years, the market scenario for Postoperative pain is set to change due to the extensive research and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.
• The companies are developing therapies that focus on novel approaches to treat/improve the disease condition, assess challenges, and seek opportunities that could influence SAF-312 dominance.
• Other emerging products for Postoperative pain are expected to give tough market competition to SAF-312 and launch of late-stage emerging therapies in the near future will significantly impact the market.
• A detailed description of regulatory milestones, and developmental activities, provide the current development scenario of SAF-312 in Postoperative pain.
• Our in-depth analysis of the forecasted sales data of SAF-312 from 2027 to 2032 will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the SAF-312 in Postoperative pain.

Key Questions:

• What is the product type, route of administration and mechanism of action of SAF-312?
• What is the clinical trial status of the study related to SAF-312 in Postoperative pain and study completion date?
• What are the key collaborations, mergers and acquisitions, licensing and other activities related to the SAF-312 development?
• What are the key designations that have been granted to SAF-312 for Postoperative pain?
• What is the forecasted market scenario of SAF-312 for Postoperative pain?
• What are the forecasted sales of SAF-312 in the seven major countries, including the United States, Europe (Germany, France, Italy, Spain) and the United Kingdom, and Japan?
• What are the other emerging products available and how are these giving competition to SAF-312 for Postoperative pain?
• Which are the late-stage emerging therapies under development for the treatment of Postoperative pain?

Table of Contents

1. Report Introduction

2. SAF-312 Overview in Postoperative pain

• 2.1. Product Detail
• 2.2. Clinical Development
  • 2.2.1. Clinical studies
  • 2.2.2. Clinical trials information
  • 2.2.3. Safety and efficacy
• 2.3. Other Developmental Activities
• 2.4. Product Profile

3. Competitive Landscape (Marketed Therapies)

4. Competitive Landscape (Late-stage Emerging Therapies)

5. SAF-312 Market Assessment

• 5.1. Market Outlook of SAF-312 in Postoperative pain
• 5.2. 7MM Analysis
  • 5.2.1. Market Size of SAF-312 in the 7MM for Postoperative pain
• 5.3. Country-wise Market Analysis
  • 5.3.1. Market Size of SAF-312 in the United States for Postoperative pain
  • 5.3.2. Market Size of SAF-312 in Germany for Postoperative pain
  • 5.3.3. Market Size of SAF-312 in France for Postoperative pain
  • 5.3.4. Market Size of SAF-312 in Italy for Postoperative pain
  • 5.3.5. Market Size of SAF-312 in Spain for Postoperative pain
  • 5.3.6. Market Size of SAF-312 in the United Kingdom for Postoperative pain
  • 5.3.7. Market Size of SAF-312 in Japan for Postoperative pain

6. SWOT Analysis

7. Analysts' Views

8. Appendix

• 8.1. Bibliography
• 8.2. Report Methodology

9. DelveInsight Capabilities

10. Disclaimer

11. About DelveInsight

12. Report Purchase Options